Recent Updates — MCK
Clayton, Dubilier & Rice (CD&R) and McKesson Corporation have entered into a definitive agreement to acquire Option Care Health, an independent provider of home and alternate site infusion services, for $32.05 per share in cash. The transaction values the target at approximately $5.8 billion in total enterprise value. CD&R will hold a majority ownership interest of approximately 51%, while McKesson will invest roughly $1.4 billion to acquire a minority stake of 49%. Option Care Health will remain an independent, privately held company led by its existing management team following the expected close in the first half of calendar year 2027, subject to customary closing conditions including stockholder approval and regulatory clearances. McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere.
McKesson Corporation reported preliminary results for the fiscal 2027 first quarter ended June 30, 2026. Consolidated revenues increased 8% to $105.4 billion, driven by growth in North American Pharmaceutical and Oncology & Multispecialty segments. Adjusted earnings per diluted share rose 20% to $9.93, while GAAP earnings per diluted share decreased 18% to $5.15 due to a $293 million redemption value adjustment for redeemable non-controlling interests. The company raised its full-year adjusted EPS guidance to $44.20–$45.00 from the previous range of $43.80–$44.60. McKesson returned $2.6 billion to shareholders, including $2.5 billion in stock repurchases and a 15% dividend increase to $0.94 per share. Additionally, the company announced the name Wellverse for its planned separated Medical-Surgical Solutions business and completed a $1.25 billion minority interest sale of that segment to Apollo Funds. McKesson Corporation operates as a diversified healthcare services leader providing pharmaceutical distribution, biopharma services, and medical-surgical solutions.
Thomas L. Rodgers, Executive Vice President, Chief Strategy and Business Development Officer, announced his intention to retire effective August 1, 2026. To facilitate a transition, Ramesh Srinivasan will be appointed as Executive Vice President, Chief Strategy Officer, also effective August 1, 2026. McKesson Corporation is a healthcare company providing pharmaceutical and medical supplies distribution.
On June 9, 2026, McKesson Medical-Surgical Top Holdings, Inc., a subsidiary of McKesson Corporation, entered into an amendment to its existing Credit Agreement with JPMorgan Chase Bank, N.A. as administrative agent. The amendment establishes a $2,250.0 million senior secured term "B" loan facility due in 2032. Borrowings under this facility carry an interest rate at the Borrower's option of either the Adjusted Term SOFR Rate plus 2.25% per annum or the Base Rate plus 1.25% per annum. The facility is secured by substantially all tangible and intangible assets of the Borrower and its material U.S. subsidiaries. McKesson Corporation is a healthcare company providing pharmaceutical and medical-surgical distribution services.